Sir,

Up to 10% of patients with renal clear cell carcinoma (RCC) have intracaval neoplastic extension (ICNE). Caval thrombectomy is associated with a 7.5% early mortality and requires a multidisciplinary surgical team, with the use of cardiopulmonary bypass (CPB). Furthermore, this surgical option has not revealed any substantial impact on the long-term survival of patients \[[@R1]\]. We report a favourable outcome of recurrent ICNE under sorafenib treatment, in a patient who had previously undergone surgery.

A 62-year-old man was diagnosed in May 2006 with ICNE secondary to left RCC. He underwent a nephrectomy and removal of intracaval thrombosis extending into the right atrium. Postoperative serum creatinine level was 1.70 mg/dL. Pathological exam confirmed the neoplastic nature of the thrombus related to RCC. Despite thrombolytic agents followed by anticoagulant treatment, ICNE recurred 2 months later, with right renal vena extension inducing oliguric acute renal failure (serum creatinine, 7.38 mg/dL), and required iterative haemodialysis. Despite a 5-month compassionate use of sunitinib 37.5 mg daily and maintained anticoagulation, ICNE remained stable ([Figure 1](#F1){ref-type="fig"}A) and the patient remained haemodialysis dependent. In January 2007, he was then treated with sorafenib 400 mg twice a day. Three months after the start of the treatment, his pre-haemodialysis serum creatinine level decreased from 5.63 to 1.77 mg/dL, and he became free of dialysis up to the present. Magnetic resonance nuclear imaging revealed a reduction of the thrombus mass ([Figure 1](#F1){ref-type="fig"}B) compared to the pre-sorafenib treatment: the transversal diameter of the caval and renal veins, from 32 to 22 mm and from 22 to 18 mm, respectively.

![T1 gadolinium sequence of MRI (A) showing thrombus in the right renal vein before sorafenib treatment, (B) reduction of the thrombus mass and partially reperfused right renal vein at 12 weeks of sorafenib treatment.](sfm004fig1){#F1}

In our patient, sorafenib-induced thrombus regression suggests a role for angiogenesis in this process. Indeed, activation of intracellular signalling (phosphoinositol 3P, Ras/Raf kinase and MAP kinase) pathways mediated by the expression of tissue factor, a thrombotic key factor, has been linked to tumour progression \[[@R2]\]. Because oncogenic activation of the Ras/Raf pathway may lead to a sustained proliferative signal resulting in tumour growth and progression, inhibition of this pathway may represent an attractive approach for ICNE treatment. Furthermore, vascular endothelial growth factor (VEGF) was found to be increased after retinal vein occlusion \[[@R4]\] and intra-vitreal injection of bevacizumab, an anti-VEGF antibody, can improve visual acuity in those patients. In analogy to this condition, we hypothesized that in our patient, sorafenib, an orally active multi-kinase inhibitor, initially identified as a Raf kinase inhibitor, might have induced the partial resolution of venous thrombus and its extension in the renal vein, thus leading to renal function recovery.
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